A Morningstar analyst says Fisher & Paykel Healthcare is poised to grow, with a rising currency the only impediment, reports New Zealand-based Otago Daily Times.
The listed New Zealand company was expanding its medical device range with the aim of improving care and outcomes for patients in an increasing range of applications, in both the hospital and home-care setting.
The firm’s strong competitive position in respiratory and acute care (Rac), along with its ability to churn out innovative new products, would propel returns in the long run, he said.
